Onset of Marine-Lenhart syndrome and Graves' ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis.
Adult
Alemtuzumab
/ adverse effects
Antineoplastic Agents, Immunological
/ adverse effects
Antithyroid Agents
/ administration & dosage
Female
Graves Disease
/ complications
Graves Ophthalmopathy
/ chemically induced
Humans
Methimazole
/ administration & dosage
Methionine
/ administration & dosage
Multiple Sclerosis
/ drug therapy
Organoselenium Compounds
/ administration & dosage
Alemtuzumab
Graves’ ophthalmopathy
Immune-reconstitution inflammatory syndrome
Marine-Lenhart syndrome
Journal
Hormones (Athens, Greece)
ISSN: 2520-8721
Titre abrégé: Hormones (Athens)
Pays: Switzerland
ID NLM: 101142469
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
01
04
2020
accepted:
20
05
2020
pubmed:
6
6
2020
medline:
29
10
2021
entrez:
6
6
2020
Statut:
ppublish
Résumé
Immune checkpoint blockade therapy may lead to thyroid dysfunction in 3-7% of treated patients. Alemtuzumab is a CD52 inhibitor leading to thyroid dysfunction in approximately 40% of patients. A female patient was affected by multiple sclerosis (MS) and subclinical hyperthyroidism due to an autonomously functioning thyroid nodule (AFTN). After alemtuzumab treatment, she developed aggressive clinical hyperthyroidism consistent with Marine-Lenhart syndrome. A 36-year-old woman presented in July 2019 with symptoms of hyperthyroidism and eye complaints. Three years earlier, she was diagnosed with MS. Subclinical hyperthyroidism was diagnosed in April 2017. Thyroid scintigraphy showed an intranodular distribution of We present a case of Graves' disease with active, moderate-to-severe Graves' ophthalmopathy in a patient with pre-existing AFTN presenting with a coexisting, rare case of Marine-Lenhart syndrome associated with immune reconstitution after alemtuzumab treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint blockade therapy may lead to thyroid dysfunction in 3-7% of treated patients. Alemtuzumab is a CD52 inhibitor leading to thyroid dysfunction in approximately 40% of patients. A female patient was affected by multiple sclerosis (MS) and subclinical hyperthyroidism due to an autonomously functioning thyroid nodule (AFTN). After alemtuzumab treatment, she developed aggressive clinical hyperthyroidism consistent with Marine-Lenhart syndrome.
CASE PRESENTATION
METHODS
A 36-year-old woman presented in July 2019 with symptoms of hyperthyroidism and eye complaints. Three years earlier, she was diagnosed with MS. Subclinical hyperthyroidism was diagnosed in April 2017. Thyroid scintigraphy showed an intranodular distribution of
CONCLUSION
CONCLUSIONS
We present a case of Graves' disease with active, moderate-to-severe Graves' ophthalmopathy in a patient with pre-existing AFTN presenting with a coexisting, rare case of Marine-Lenhart syndrome associated with immune reconstitution after alemtuzumab treatment.
Identifiants
pubmed: 32500462
doi: 10.1007/s42000-020-00215-9
pii: 10.1007/s42000-020-00215-9
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Antithyroid Agents
0
Organoselenium Compounds
0
methionine selenoxide
0
Alemtuzumab
3A189DH42V
Methimazole
554Z48XN5E
Methionine
AE28F7PNPL
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-165Références
Wiersinga WM (2016) Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. Endocrinol Metab 31:213–222
doi: 10.3803/EnM.2016.31.2.213
Barroso-Sousa R, Barry WT, Garrido-Castro AC et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4:173–182
doi: 10.1001/jamaoncol.2017.3064
Barroso-Sousa R, Ott PA, Hodi FS et al (2018) Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer 124:1111–1121
doi: 10.1002/cncr.31200
Castinetti F, Albarel F, Archambeaud F et al (2019) French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer 26:G1–G18
doi: 10.1530/ERC-18-0320
Coles AJ, Wing M, Smith S et al (1999) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354:1691–1695
doi: 10.1016/S0140-6736(99)02429-0
Pariani N, Willis M, Muller I et al (2018) Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. J Clin Endocrinol Metab 103:3010–3018
doi: 10.1210/jc.2018-00359
Daniels GH, Vladic A, Brinar V et al (2014) Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 99:80–89
doi: 10.1210/jc.2013-2201
Rotondi M, Molteni M, Leporati P et al (2017) Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-TSH-receptor immune response. Front Endocrinol 8:254
doi: 10.3389/fendo.2017.00254
Scappaticcio L, Castellana M, Virili C et al (2020) Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. J Endocrinol Investig 43:219–229
doi: 10.1007/s40618-019-01105-7
Decallonne B, Bartholomé E, Delvaux V et al (2018) Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management. Acta Neurol Belg 118:153–159
doi: 10.1007/s13760-018-0883-2
Marine D, Lenhart CH (1911) Pathological anatomy of exophthalmic goiter: the anatomical and physiological relations of the thyroid gland to the disease; the treatment. Arch Intern Med 8:265–316
doi: 10.1001/archinte.1911.00060090002001
Neuman D, Kuker R, Vendrame F (2018) Marine-Lenhart syndrome: case report, diagnosis, and management. Case Rep Endocrinol 2018:
Wiersinga WM, Perros P, Kahaly GJ et al (2006) Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155:387–389
doi: 10.1530/eje.1.02230
Malago R, D’Onofrio M, Ferdeghini M et al (2008) Thyroid volumetric quantification: comparative evaluation between conventional and volumetric ultrasonography. J Ultrasound Med 27:1727–1733
doi: 10.7863/jum.2008.27.12.1727
Sparano C, Parenti G, Cilotti A et al (2019) Clinical impact of the new SIAPEC-IAP classification on the indeterminate category of thyroid nodules. J Endocrinol Investig 42:1–6
doi: 10.1007/s40618-018-0871-7
Lorenzi AR, Clarke AM, Wooldridge T et al (2008) Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. Arthritis Rheum Off J Am Coll Rheumatol 58:370–375
doi: 10.1002/art.23122
Cossburn M, Pace AA, Jones J et al (2011) Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77:573–579
doi: 10.1212/WNL.0b013e318228bec5
Weetman AP (2014) Graves’ disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently? Clin Endocrinol 80:629–632
doi: 10.1111/cen.12427
Abraham P, Avenell A, McGeoch SC, et al (2010) Antithyroid drug regimen for treating graves’ hyperthyroidism. Cochrane Database Syst Rev